

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PERJETA safely and effectively. See full prescribing information for PERJETA.

**PERJETA® (pertuzumab)**  
**Injection, for intravenous use**  
**Initial U.S. Approval: 2012**

### WARNING: EMBRYO-FETAL TOXICITY

*See full prescribing information for complete boxed warning.*

**Exposure to PERJETA can result in embryo-fetal death and birth defects. Studies in animals have resulted in oligohydramnios, delayed renal development, and death. Advise patients of these risks and the need for effective contraception. (5.1, 8.1, 8.6)**

### RECENT MAJOR CHANGES

Dosage and Administration (2.1) 04/2013

### INDICATIONS AND USAGE

PERJETA is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (1)

### DOSAGE AND ADMINISTRATION

- **For intravenous infusion only.** Do not administer as an intravenous push or bolus. (2.3)
- The initial dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusion. (2.1)

### DOSAGE FORMS AND STRENGTHS

- 420 mg/14 mL single-use vial. (3)

## CONTRAINDICATIONS

None. (4)

## WARNINGS AND PRECAUTIONS

- Embryo-fetal toxicity: Fetal harm can occur when administered to a pregnant woman. (5.1, 8.1)
- Left Ventricular Dysfunction: Monitor LVEF and withhold dosing as appropriate. (5.2, 6.1)
- Infusion-Associated Reactions, Hypersensitivity Reactions/Anaphylaxis: Monitor for signs and symptoms. If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies. (5.3)
- HER2 testing: Perform using FDA-approved tests by laboratories with demonstrated proficiency. (5.4)

## ADVERSE REACTIONS

The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## USE IN SPECIFIC POPULATIONS

- Nursing mothers: Discontinue nursing or discontinue PERJETA, taking into consideration the importance of the drug to the mother. (8.3)
- Females of Reproductive Potential: Counsel females on pregnancy prevention and planning. Encourage patient participation in the MoHER Pregnancy Registry by contacting 1-800-690-6720. (5.1, 8.1, 8.6, 17)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 04/2013**

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### WARNING: EMBRYO-FETAL TOXICITY

#### 1 INDICATIONS AND USAGE

#### 2 DOSAGE AND ADMINISTRATION

- 2.1 Recommended Doses and Schedules
- 2.2 Dose Modification
- 2.3 Preparation for Administration

#### 3 DOSAGE FORMS AND STRENGTHS

#### 4 CONTRAINDICATIONS

#### 5 WARNINGS AND PRECAUTIONS

- 5.1 Embryo-Fetal Toxicity
- 5.2 Left Ventricular Dysfunction
- 5.3 Infusion-Associated Reactions, Hypersensitivity Reactions/Anaphylaxis
- 5.4 HER2 Testing

#### 6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Immunogenicity

#### 7 DRUG INTERACTIONS

#### 8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use

#### 8.5 Geriatric Use

#### 8.6 Females of Reproductive Potential

#### 8.7 Renal Impairment

#### 8.8 Hepatic Impairment

#### 10 OVERDOSAGE

#### 11 DESCRIPTION

#### 12 CLINICAL PHARMACOLOGY

##### 12.1 Mechanism of Action

##### 12.3 Pharmacokinetics

##### 12.6 Cardiac Electrophysiology

#### 13 NONCLINICAL TOXICOLOGY

##### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### 14 CLINICAL STUDIES

##### 14.1 Metastatic Breast Cancer

#### 16 HOW SUPPLIED/STORAGE AND HANDLING

##### 16.1 How Supplied

#### 17 PATIENT COUNSELING INFORMATION

\* Sections or subsections omitted from the Full Prescribing Information are not listed.

## FULL PRESCRIBING INFORMATION

### WARNING: EMBRYO-FETAL TOXICITY

Exposure to PERJETA can result in embryo-fetal death and birth defects. Studies in animals have resulted in oligohydramnios, delayed renal development, and death. Advise patients of these risks and the need for effective contraception. (5.1, 8.1, 8.6)

## 1 INDICATIONS AND USAGE

PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Recommended Doses and Schedules

The initial dose of PERJETA is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.

When administered with PERJETA, the recommended initial dose of trastuzumab is 8 mg/kg administered as a 90-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 6 mg/kg administered as an intravenous infusion over 30 to 90 minutes.

When administered with PERJETA, the recommended initial dose of docetaxel is 75 mg/m<sup>2</sup> administered as an intravenous infusion. The dose may be escalated to 100 mg/m<sup>2</sup> administered every 3 weeks if the initial dose is well tolerated.

PERJETA, trastuzumab, and docetaxel should be administered sequentially. PERJETA and trastuzumab can be given in any order. Docetaxel should be administered after PERJETA and trastuzumab. An observation period of 30 to 60 minutes is recommended after each PERJETA infusion and before commencement of any subsequent infusion of trastuzumab or docetaxel [see *Warnings and Precautions* (5.3)].

### 2.2 Dose Modification

For delayed or missed doses, if the time between two sequential infusions is less than 6 weeks, the 420 mg dose of PERJETA should be administered. Do not wait until the next planned dose. If the time between two sequential infusions is 6 weeks or more, the initial dose of 840 mg PERJETA should be re-administered as a 60-minute intravenous infusion followed every 3 weeks thereafter by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.

The infusion rate of PERJETA may be slowed or interrupted if the patient develops an infusion-associated reaction. The infusion should be discontinued immediately if the patient experiences a serious hypersensitivity reaction [see *Warnings and Precautions* (5.3)].

### *Left Ventricular Ejection Fraction (LVEF):*

Withhold PERJETA and trastuzumab dosing for at least 3 weeks for either:

- a drop in LVEF to less than 40% or

- LVEF of 40% to 45% with a 10% or greater absolute decrease below pretreatment values  
[see Warnings and Precautions (5.2)]

PERJETA may be resumed if the LVEF has recovered to greater than 45% or to 40% to 45% associated with less than a 10% absolute decrease below pretreatment values.

If after a repeat assessment within approximately 3 weeks, the LVEF has not improved, or has declined further, discontinuation of PERJETA and trastuzumab should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks [see Warnings and Precautions (5.2)].

PERJETA should be withheld or discontinued if trastuzumab treatment is withheld or discontinued.

If docetaxel is discontinued, treatment with PERJETA and trastuzumab may continue.

Dose reductions are not recommended for PERJETA.

For docetaxel dose modifications, see docetaxel prescribing information.

## **2.3 Preparation for Administration**

Administer as an intravenous infusion only. Do not administer as an intravenous push or bolus. Do not mix PERJETA with other drugs.

### **Preparation**

Prepare the solution for infusion, using aseptic technique, as follows:

- Parenteral drug products should be inspected visually for particulates and discoloration prior to administration.
- Withdraw the appropriate volume of PERJETA solution from the vial(s).
- Dilute into a 250 mL 0.9% sodium chloride PVC or non-PVC polyolefin infusion bag.
- Mix diluted solution by gentle inversion. Do not shake.
- Administer immediately once prepared.
- If the diluted infusion solution is not used immediately, it can be stored at 2°C to 8°C for up to 24 hours.
- Dilute with 0.9% Sodium Chloride injection only. Do not use dextrose (5%) solution.

## **3 DOSAGE FORMS AND STRENGTHS**

PERJETA (pertuzumab) 420 mg/14 mL (30 mg/mL) in a single-use vial

## **4 CONTRAINDICATIONS**

None.

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Embryo-Fetal Toxicity**

PERJETA can cause fetal harm when administered to a pregnant woman. Treatment of pregnant cynomolgus monkeys with pertuzumab resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal death. If PERJETA is administered during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1)].

Verify pregnancy status prior to the initiation of PERJETA. Advise patients of the risks of embryo-fetal death and birth defects and the need for contraception during and after treatment. Advise patients to contact their healthcare provider immediately if they suspect they may be pregnant. If PERJETA is administered during pregnancy or if a patient becomes pregnant while receiving PERJETA, immediately report exposure to the Genentech Adverse Event Line at 1-888-835-2555. Encourage women who may be exposed during pregnancy to enroll in the MoTHER Pregnancy Registry by contacting 1-800-690-6720 [see *Patient Counseling Information* (17)].

Monitor patients who become pregnant during PERJETA therapy for oligohydramnios. If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care. The efficacy of intravenous hydration in the management of oligohydramnios due to PERJETA exposure is not known.

## **5.2 Left Ventricular Dysfunction**

Decreases in LVEF have been reported with drugs that block HER2 activity, including PERJETA. In the randomized trial, PERJETA in combination with trastuzumab and docetaxel was not associated with increases in the incidence of symptomatic left ventricular systolic dysfunction (LVSD) or decreases in LVEF compared with placebo in combination with trastuzumab and docetaxel [see *Clinical Studies* (14.1)]. Left ventricular dysfunction occurred in 4.4% of patients in the PERJETA-treated group and 8.3% of patients in the placebo-treated group. Symptomatic left ventricular systolic dysfunction (congestive heart failure) occurred in 1.0% of patients in the PERJETA-treated group and 1.8% of patients in the placebo-treated group [see *Adverse Reactions* (6.1)]. Patients who have received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF.

PERJETA has not been studied in patients with a pretreatment LVEF value of  $\leq 50\%$ , a prior history of CHF, decreases in LVEF to  $< 50\%$  during prior trastuzumab therapy, or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to  $> 360 \text{ mg/m}^2$  of doxorubicin or its equivalent.

Assess LVEF prior to initiation of PERJETA and at regular intervals (e.g., every three months) during treatment to ensure that LVEF is within the institution's normal limits. If LVEF is  $< 40\%$ , or is  $40\%$  to  $45\%$  with a  $10\%$  or greater absolute decrease below the pretreatment value, withhold PERJETA and trastuzumab and repeat LVEF assessment within approximately 3 weeks. Discontinue PERJETA and trastuzumab if the LVEF has not improved or has declined further, unless the benefits for the individual patient outweigh the risks [see *Dosage and Administration* (2.2)].

## **5.3 Infusion-Associated Reactions, Hypersensitivity Reactions/Anaphylaxis**

PERJETA has been associated with infusion and hypersensitivity reactions [see *Adverse Reactions* (6.1)]. An infusion reaction was defined in the randomized trial as any event described as hypersensitivity, anaphylactic reaction, acute infusion reaction or cytokine release syndrome occurring during an infusion or on the same day as the infusion. The initial dose of PERJETA was given the day before trastuzumab and docetaxel to allow for the examination of PERJETA-associated reactions. On the first day, when only PERJETA was administered, the overall frequency of infusion reactions was  $13.0\%$  in the PERJETA-treated group and  $9.8\%$  in the placebo-treated group. Less than  $1\%$  were grade 3 or 4. The most common infusion reactions ( $\geq 1.0\%$ ) were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity, and vomiting.

During the second cycle when all drugs were administered on the same day, the most common infusion reactions in the PERJETA-treated group ( $\geq 1.0\%$ ) were fatigue, dysgeusia, hypersensitivity, myalgia, and vomiting.

In the randomized trial, the overall frequency of hypersensitivity/anaphylaxis reactions was 10.8% in the PERJETA-treated group and 9.1% in the placebo-treated group. The incidence of Grade 3 – 4 hypersensitivity/anaphylaxis reactions was 2% in the PERJETA-treated group and 2.5% in the placebo-treated group according to National Cancer Institute – Common Terminology Criteria for Adverse Events (NCI - CTCAE) (version 3). Overall, 4 patients in PERJETA-treated group and 2 patients in the placebo-treated group experienced anaphylaxis.

Observe patients closely for 60 minutes after the first infusion and for 30 minutes after subsequent infusions of PERJETA. If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies. Monitor patients carefully until complete resolution of signs and symptoms. Consider permanent discontinuation in patients with severe infusion reactions [*see Dosage and Administration (2.2)*].

#### **5.4 HER2 Testing**

Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy because these are the only patients studied and for whom benefit has been shown [*see Indications and Usage (1) and Clinical Studies (14)*]. In the randomized trial, patients with breast cancer were required to have evidence of HER2 overexpression defined as 3+ IHC by Dako Herceptest™ or FISH amplification ratio  $\geq 2.0$  by Dako HER2 FISH PharmDx™ test kit. Only limited data were available for patients whose breast cancer was positive by FISH, but did not demonstrate protein overexpression by IHC.

Assessment of HER2 status should be performed by laboratories with demonstrated proficiency in the specific technology being utilized. Improper assay performance, including use of sub-optimally fixed tissue, failure to utilize specified reagents, deviation from specific assay instructions, and failure to include appropriate controls for assay validation, can lead to unreliable results.

### **6 ADVERSE REACTIONS**

The following adverse reactions are discussed in greater detail in other sections of the label:

- Embryo-Fetal Toxicity [*see Warnings and Precautions (5.1)*]
- Left Ventricular Dysfunction [*see Warnings and Precautions (5.2)*]
- Infusion-Associated Reactions, Hypersensitivity Reactions/Anaphylaxis [*see Warnings and Precautions (5.3)*]

#### **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In clinical trials, PERJETA has been evaluated in more than 1400 patients with various malignancies and treatment with PERJETA was predominantly in combination with other anti-neoplastic agents.

The adverse reactions described in Table 1 were identified in 804 patients with HER2-positive metastatic breast cancer treated in the randomized trial. Patients were randomized to receive either PERJETA in combination with trastuzumab and docetaxel or placebo in combination with

trastuzumab and docetaxel. The median duration of study treatment was 18.1 months for patients in the PERJETA-treated group and 11.8 months for patients in the placebo-treated group. No dose adjustment was permitted for PERJETA or trastuzumab. The rates of adverse events resulting in permanent discontinuation of all study therapy were 6.1% for patients in the PERJETA-treated group and 5.3% for patients in the placebo-treated group. Adverse events led to discontinuation of docetaxel alone in 23.6% of patients in the PERJETA-treated group and 23.2% of patients in the placebo-treated group. Table 1 reports the adverse reactions that occurred in at least 10% of patients in the PERJETA-treated group.

The most common adverse reactions (> 30%) seen with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. The most common NCI - CTCAE (version 3) Grade 3 – 4 adverse reactions (> 2%) were neutropenia, febrile neutropenia, leukopenia, diarrhea, peripheral neuropathy, anemia, asthenia, and fatigue. An increased incidence of febrile neutropenia was observed for Asian patients in both treatment arms compared with patients of other races and from other geographic regions. Among Asian patients, the incidence of febrile neutropenia was higher in the pertuzumab-treated group (26%) compared with the placebo-treated group (12%).

180  
181

**Table 1**      **Summary of Adverse Reactions Occurring in  $\geq 10\%$  of Patients on the PERJETA Treatment Arm in the Randomized Trial**

Body System/Adverse Reactions	PERJETA + trastuzumab + docetaxel  n=407		Placebo + trastuzumab + docetaxel  n=397	
	Frequency rate %		Frequency rate %	
	All Grades %	Grades 3 – 4 %	All Grades %	Grades 3 – 4 %
<b>General disorders and administration site conditions</b>				
Fatigue	37.6	2.2	36.8	3.3
Asthenia	26.0	2.5	30.2	1.5
Edema peripheral	23.1	0.5	30.0	0.8
Mucosal inflammation	27.8	1.5	19.9	1.0
Pyrexia	18.7	1.2	17.9	0.5
<b>Skin and subcutaneous tissue disorders</b>				
Alopecia	60.9	0.0	60.5	0.3
Rash	33.7	0.7	24.2	0.8
Nail disorder	22.9	1.2	22.9	0.3
Pruritus	14.0	0.0	10.1	0.0
Dry skin	10.6	0.0	4.3	0.0
<b>Gastrointestinal disorders</b>				
Diarrhea	66.8	7.9	46.3	5.0
Nausea	42.3	1.2	41.6	0.5
Vomiting	24.1	1.5	23.9	1.5
Constipation	15.0	0.0	24.9	1.0
Stomatitis	18.9	0.5	15.4	0.3
<b>Blood and lymphatic system disorders</b>				
Neutropenia	52.8	48.9	49.6	45.8
Anemia	23.1	2.5	18.9	3.5
Leukopenia	18.2	12.3	20.4	14.6
Febrile neutropenia*	13.8	13.0	7.6	7.3
<b>Nervous system disorders</b>				
Neuropathy peripheral	32.4	3.2	33.8	2.0
Headache	20.9	1.2	16.9	0.5
Dysgeusia	18.4	0.0	15.6	0.0
Dizziness	12.5	0.5	12.1	0.0
<b>Musculoskeletal and connective tissue</b>				

<b>disorders</b>				
Myalgia	22.9	1.0	23.9	0.8
Arthralgia	15.5	0.2	16.1	0.8
<b>Infections and infestations</b>				
Upper respiratory tract infection	16.7	0.7	13.4	0.0
Nasopharyngitis	11.8	0.0	12.8	0.3
<b>Respiratory, thoracic and mediastinal disorders</b>				
Dyspnea	14.0	1.0	15.6	2.0
<b>Metabolism and nutrition disorders</b>				
Decreased appetite	29.2	1.7	26.4	1.5
<b>Eye disorders</b>				
Lacrimation increased	14.0	0.0	13.9	0.0
<b>Psychiatric disorders</b>				
Insomnia	13.3	0.0	13.4	0.0

\* In this table this denotes an adverse reaction that has been reported in association with a fatal outcome

**The following clinically relevant adverse reactions were reported in < 10% of patients in the PERJETA-treated group:**

**Skin and subcutaneous tissue disorders:** Paronychia (7.1% in the PERJETA-treated group vs. 3.5% in the placebo-treated group)

**Respiratory, thoracic and mediastinal disorders:** Pleural effusion (5.2% in the PERJETA-treated group vs. 5.8% in the placebo-treated group)

**Cardiac disorders:** Left ventricular dysfunction (4.4% in the PERJETA-treated group vs. 8.3% in the placebo-treated group) including symptomatic left ventricular systolic dysfunction (CHF) (1.0% in the PERJETA-treated group vs. 1.8% in the placebo-treated group)

**Immune system disorders:** Hypersensitivity (10.1% in the PERJETA-treated group vs. 8.6% in placebo-treated group)

#### ***Adverse Reactions Reported in Patients Receiving PERJETA and Trastuzumab after Discontinuation of Docetaxel***

In the randomized trial, adverse reactions were reported less frequently after discontinuation of docetaxel treatment. All adverse reactions in the PERJETA and trastuzumab treatment group occurred in < 10% of patients with the exception of diarrhea (19.1%), upper respiratory tract infection (12.8%), rash (11.7%), headache (11.4%), and fatigue (11.1%).

## **6.2 Immunogenicity**

As with all therapeutic proteins, there is the potential for an immune response to PERJETA.

Patients in the randomized trial were tested at multiple time-points for antibodies to PERJETA. Approximately 2.8% (11/386) of patients in the PERJETA-treated group and 6.2% (23/372) of patients in the placebo-treated group tested positive for anti-PERJETA antibodies. Of these



34 patients, none experienced anaphylactic/hypersensitivity reactions that were clearly related to the anti-therapeutic antibodies (ATA). The presence of pertuzumab in patient serum at the levels expected at the time of ATA sampling can interfere with the ability of this assay to detect anti-pertuzumab antibodies. In addition, the assay may be detecting antibodies to trastuzumab. As a result, data may not accurately reflect the true incidence of anti-pertuzumab antibody development.

Immunogenicity data are highly dependent on the sensitivity and specificity of the test methods used. Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication, and the underlying disease. For these reasons, comparison of the incidence of antibodies to PERJETA with the incidence of antibodies to other products may be misleading.

## **7 DRUG INTERACTIONS**

No drug-drug interactions were observed between pertuzumab and trastuzumab, or between pertuzumab and docetaxel.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### ***Pregnancy Category D***

##### Risk Summary

There are no adequate and well-controlled studies of PERJETA in pregnant women. Based on findings in animal studies, PERJETA can cause fetal harm when administered to a pregnant woman. The effects of PERJETA are likely to be present during all trimesters of pregnancy. Pertuzumab administered to pregnant cynomolgus monkeys resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal deaths at clinically relevant exposures of 2.5 to 20-fold greater than the recommended human dose, based on  $C_{max}$ . If PERJETA is administered during pregnancy, or if a patient becomes pregnant while receiving PERJETA, the patient should be apprised of the potential hazard to the fetus.

If PERJETA is administered during pregnancy or if a patient becomes pregnant while receiving PERJETA, immediately report exposure to the Genentech Adverse Event Line at 1-888-835-2555. Encourage women who may be exposed during pregnancy to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 [*see Patient Counseling Information (17)*].

##### Animal Data

Reproductive toxicology studies have been conducted in cynomolgus monkeys. Pregnant monkeys were treated on Gestational Day (GD)19 with loading doses of 30 to 150 mg/kg pertuzumab, followed by bi-weekly doses of 10 to 100 mg/kg. These dose levels resulted in clinically relevant exposures of 2.5 to 20-fold greater than the recommended human dose, based on  $C_{max}$ . Intravenous administration of pertuzumab from GD19 through GD50 (period of organogenesis) was embryotoxic, with dose-dependent increases in embryo-fetal death between GD25 to GD70. The incidences of embryo-fetal loss were 33, 50, and 85% for dams treated with bi-weekly pertuzumab doses of 10, 30, and 100 mg/kg, respectively (2.5 to 20-fold greater than the recommended human dose, based on  $C_{max}$ ). At Caesarean section on GD100, oligohydramnios, decreased relative lung and kidney weights and microscopic evidence of renal hypoplasia consistent with delayed renal development were identified in all pertuzumab dose

groups. Pertuzumab exposure was reported in offspring from all treated groups, at levels of 29% to 40% of maternal serum levels at GD100.

### **8.3 Nursing Mothers**

It is not known whether PERJETA is excreted in human milk, but human IgG is excreted in human milk. Because many drugs are secreted in human milk and because of the potential for serious adverse reactions in nursing infants from PERJETA, a decision should be made whether to discontinue nursing, or discontinue drug, taking into account the elimination half-life of PERJETA and the importance of the drug to the mother [*See Warnings and Precautions (5.1), Clinical Pharmacology (12.3)*].

### **8.4 Pediatric Use**

The safety and effectiveness of PERJETA have not been established in pediatric patients.

### **8.5 Geriatric Use**

Of 402 patients who received PERJETA in the randomized trial, 60 patients (15%) were  $\geq 65$  years of age and 5 patients (1%) were  $\geq 75$  years of age. No overall differences in efficacy and safety of PERJETA were observed between these patients and younger patients.

Based on a population pharmacokinetic analysis, no significant difference was observed in the pharmacokinetics of pertuzumab between patients  $< 65$  years ( $n=306$ ) and patients  $\geq 65$  years ( $n=175$ ).

### **8.6 Females of Reproductive Potential**

PERJETA can cause embryo-fetal harm when administered during pregnancy. Counsel patients regarding pregnancy prevention and planning. Advise females of reproductive potential to use effective contraception while receiving PERJETA and for 6 months following the last dose of PERJETA.

If PERJETA is administered during pregnancy or if a patient becomes pregnant while receiving PERJETA, immediately report exposure to the Genentech Adverse Event Line at 1-888-835-2555. Encourage women who may be exposed during pregnancy to enroll in the MoTHER Pregnancy Registry by contacting 1-800-690-6720 [*see Patient Counseling Information (17)*].

### **8.7 Renal Impairment**

Dose adjustments of PERJETA are not needed in patients with mild (creatinine clearance [CLcr] 60 to 90 mL/min) or moderate (CLcr 30 to 60 mL/min) renal impairment. No dose adjustment can be recommended for patients with severe renal impairment (CLcr less than 30 mL/min) because of the limited pharmacokinetic data available [*see Clinical Pharmacology (12.3)*].

### **8.8 Hepatic Impairment**

No clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of pertuzumab.

## **10 OVERDOSAGE**

No drug overdoses have been reported with PERJETA to date.

## **11 DESCRIPTION**

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab is produced by recombinant DNA technology in a mammalian cell

293 (Chinese Hamster Ovary) culture containing the antibiotic, gentamicin. Gentamicin is not  
294 detectable in the final product. Pertuzumab has an approximate molecular weight of 148 kDa.  
295 PERJETA is a sterile, clear to slightly opalescent, colorless to pale brown liquid for intravenous  
296 infusion. Each single use vial contains 420 mg of pertuzumab at a concentration of 30 mg/mL in  
297 20 mM L-histidine acetate (pH 6.0), 120 mM sucrose and 0.02% polysorbate 20.

## 298 **12 CLINICAL PHARMACOLOGY**

### 299 **12.1 Mechanism of Action**

300 Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human  
301 epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent  
302 heterodimerization of HER2 with other HER family members, including EGFR, HER3 and  
303 HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two  
304 major signal pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase  
305 (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis,  
306 respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity  
307 (ADCC).

308 While pertuzumab alone inhibited the proliferation of human tumor cells, the combination of  
309 pertuzumab and trastuzumab significantly augmented anti-tumor activity in  
310 HER2-overexpressing xenograft models.

### 311 **12.3 Pharmacokinetics**

312 Pertuzumab demonstrated linear pharmacokinetics at a dose range of 2 – 25 mg/kg. Based on a  
313 population PK analysis that included 481 patients, the median clearance (CL) of pertuzumab was  
314 0.24 L/day and the median half-life was 18 days. With an initial dose of 840 mg followed by a  
315 maintenance dose of 420 mg every three weeks thereafter, the steady-state concentration of  
316 pertuzumab was reached after the first maintenance dose.

317 The population PK analysis suggested no PK differences based on age, gender, and ethnicity  
318 (Japanese vs. non-Japanese). Baseline serum albumin level and lean body weight as covariates  
319 only exerted a minor influence on PK parameters. Therefore, no dose adjustments based on  
320 body weight or baseline albumin level are needed.

321 No drug-drug interactions were observed between pertuzumab and trastuzumab, or between  
322 pertuzumab and docetaxel in a sub-study of 37 patients in the randomized trial.

323 No dedicated renal impairment trial for PERJETA has been conducted. Based on the results of  
324 the population pharmacokinetic analysis, pertuzumab exposure in patients with mild (CLcr  
325 60 to 90 mL/min, n=200) and moderate renal impairment (CLcr 30 to 60 mL/min, n=71) were  
326 similar to those in patients with normal renal function (CLcr greater than 90 mL/min, n=200).  
327 No relationship between CLcr and pertuzumab exposure was observed over the range of  
328 observed CLcr (27 to 244 mL/min).

### 329 **12.6 Cardiac Electrophysiology**

330 The effect of pertuzumab with an initial dose of 840 mg followed by a maintenance dose of  
331 420 mg every three weeks on QTc interval was evaluated in a subgroup of 20 patients with  
332 HER2-positive breast cancer in the randomized trial. No large changes in the mean QT interval  
333 (i.e., greater than 20 ms) from placebo based on Fridericia correction method were detected in  
334 the trial. A small increase in the mean QTc interval (i.e., less than 10 ms) cannot be excluded  
335 because of the limitations of the trial design.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of pertuzumab.

Studies have not been performed to evaluate the mutagenic potential of pertuzumab.

No specific fertility studies in animals have been performed to evaluate the effect of pertuzumab.

No adverse effects on male and female reproductive organs were observed in repeat-dose toxicity studies of up to six months duration in cynomolgus monkeys.

## **14 CLINICAL STUDIES**

### **14.1 Metastatic Breast Cancer**

The randomized trial was a multicenter, double-blind, placebo-controlled trial of 808 patients with HER2-positive metastatic breast cancer. Breast tumor specimens were required to show HER2 overexpression defined as 3+ IHC or FISH amplification ratio  $\geq 2.0$  determined at a central laboratory. Patients were randomized 1:1 to receive placebo plus trastuzumab and docetaxel or PERJETA plus trastuzumab and docetaxel. Randomization was stratified by prior treatment (prior or no prior adjuvant/neoadjuvant anti-HER2 therapy or chemotherapy) and geographic region (Europe, North America, South America, and Asia). Patients with prior adjuvant or neoadjuvant therapy were required to have a disease-free interval of greater than 12 months before trial enrollment.

PERJETA was given intravenously at an initial dose of 840 mg, followed by 420 mg every 3 weeks thereafter. Trastuzumab was given intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks thereafter. Patients were treated with PERJETA and trastuzumab until progression of disease, withdrawal of consent, or unacceptable toxicity. Docetaxel was given as an initial dose of 75 mg/m<sup>2</sup> by intravenous infusion every 3 weeks for at least 6 cycles. The docetaxel dose could be escalated to 100 mg/m<sup>2</sup> at the investigator's discretion if the initial dose was well tolerated. At the time of the primary analysis, the mean number of cycles of study treatment administered was 16.2 in the placebo-treated group and 19.9 in the PERJETA-treated group.

The primary endpoint of the randomized trial was progression-free survival (PFS) as assessed by an independent review facility (IRF). PFS was defined as the time from the date of randomization to the date of disease progression or death (from any cause) if the death occurred within 18 weeks of the last tumor assessment. Additional endpoints included overall survival (OS), PFS (investigator-assessed), objective response rate (ORR) and duration of response.

Patient demographic and baseline characteristics were balanced between the treatment arms. The median age was 54 (range 22 to 89 years), 59% were White, 32% were Asian, and 4% were Black. All were women with the exception of 2 patients. Seventeen percent of patients were enrolled in North America, 14% in South America, 38% in Europe, and 31% in Asia. Tumor prognostic characteristics, including hormone receptor status (positive 48%, negative 50%), presence of visceral disease (78%) and non-visceral disease only (22%) were similar in the study arms. Approximately half of the patients received prior adjuvant or neoadjuvant anti-HER2 therapy or chemotherapy (placebo 47%, PERJETA 46%). Among patients with hormone receptor positive tumors, 45% received prior adjuvant hormonal therapy and 11% received hormonal therapy for metastatic disease. Eleven percent of patients received prior adjuvant or neoadjuvant trastuzumab.

The randomized trial demonstrated a statistically significant improvement in IRF-assessed PFS

in the PERJETA-treated group compared with the placebo-treated group [hazard ratio (HR) = 0.62 (95% CI: 0.51, 0.75),  $p < 0.0001$ ] and an increase in median PFS of 6.1 months (median PFS of 18.5 months in the PERJETA-treated group vs. 12.4 months in the placebo-treated group) (see Figure 1). The results for investigator-assessed PFS were comparable to those observed for IRF-assessed PFS.

Consistent results were observed across several patient subgroups including age ( $< 65$  or  $\geq 65$  years), race, geographic region, prior adjuvant/neoadjuvant anti-HER2 therapy or chemotherapy (yes or no), and prior adjuvant/neoadjuvant trastuzumab (yes or no). In the subgroup of patients with hormone receptor-negative disease ( $n=408$ ), the hazard ratio was 0.55 (95% CI: 0.42, 0.72). In the subgroup of patients with hormone receptor-positive disease ( $n=388$ ), the hazard ratio was 0.72 (95% CI: 0.55, 0.95). In the subgroup of patients with disease limited to non-visceral metastasis ( $n=178$ ), the hazard ratio was 0.96 (95% CI: 0.61, 1.52).

At the time of the final PFS analysis, 165 patients had died, and more deaths had occurred in the placebo-treated group (23.6%) compared with the PERJETA-treated group (17.2%); OS was not mature and interim OS analysis results did not meet the pre-specified stopping boundary for statistical significance. A second interim analysis of OS, conducted after an additional year of follow-up, demonstrated a statistically significant improvement in OS [HR=0.66 (95% CI: 0.52, 0.84),  $p=0.0008$ ]. See Table 2 and Figure 2. OS results in patient subgroups were consistent with those observed for IRF-assessed PFS with the exception of the subgroup of patients with disease limited to non-visceral metastasis [HR = 1.42 (95% CI: 0.71, 2.84)].

401

**Table 2                      Summary of Efficacy from the Randomized Trial**


<b>Parameter</b>	<b>PERJETA + trastuzumab + docetaxel n=402</b>	<b>Placebo + trastuzumab + docetaxel n=406</b>	<b>HR (95% CI)</b>	<b>p-value</b>
<b>Progression-Free Survival (independent review)</b>				
<b>No. of patients with an event</b>	191 (47.5%)	242 (59.6%)	0.62	< 0.0001
<b>Median months</b>	18.5	12.4	(0.51, 0.75)	
<b>Overall Survival (second interim analysis)</b>				
<b>No. of patients who died</b>	113 (28.1%)	154 (37.9%)	0.66	0.0008*
<b>Median months</b>	NR	37.6	(0.52, 0.84)	
<b>Objective Response Rate (ORR, independent review)</b>				
<b>No. of patients analyzed</b>	343	336		
Objective response (CR + PR)	275 (80.2%)	233 (69.3%)		
Complete response (CR)	19 (5.5%)	14 (4.2%)		
Partial Response (PR)	256 (74.6%)	219 (65.2%)		
Median Duration of Response (months)	20.2	12.5		
Difference in ORR 95% CI	10.8% (4.2%, 17.5%)			0.0011

402 \* The HR and p-value for the second interim analysis of Overall Survival crossed the pre-defined  
403 efficacy stopping boundary ( $HR \leq 0.739$ ,  $p \leq 0.0138$ ).


404 NR=Not reached

405 CI=Confidence Interval

**Figure 1** Kaplan-Meier Curve of IRF-Assessed Progression-Free Survival for the Randomized Trial



**Figure 2** Kaplan-Meier Curve of Overall Survival for the Randomized Trial



413 **16 HOW SUPPLIED/STORAGE AND HANDLING**

414 **16.1 How Supplied**

415 PERJETA is supplied as a 420 mg/14 mL (30 mg/mL) single-use vial containing preservative-free solution. NDC 50242-145-01.

417 Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use.

418 Keep vial in the outer carton in order to protect from light.

419 **DO NOT FREEZE. DO NOT SHAKE.**

420 **17 PATIENT COUNSELING INFORMATION**

- 421 • Advise pregnant women and females of reproductive potential that PERJETA exposure can  
422 result in fetal harm, including embryo-fetal death or birth defects [*see Warnings and*  
423 *Precautions (5.1) and Use in Specific Populations (8.1)*]
- 424 • Advise females of reproductive potential to use effective contraception while receiving  
425 PERJETA and for 6 months following the last dose of PERJETA [*see Warnings and*  
426 *Precautions (5.1) and Use in Special Populations (8.6)*]
- 427 • Advise nursing mothers treated with PERJETA to discontinue nursing or discontinue  
428 PERJETA, taking into account the importance of the drug to the mother [*see Use in Specific*  
429 *Populations (8.3)*].
- 430 • Encourage women who are exposed to PERJETA during pregnancy to enroll in the MoTHER  
431 Pregnancy Registry by contacting 1-800-690-6720 [*see Warnings and Precautions (5.1) and*  
432 *Use in Specific Populations (8.1)*]

---

PERJETA® (pertuzumab)

L01XC13

Manufactured by:

**Genentech, Inc.**

A Member of the Roche Group

1 DNA Way

South San Francisco, CA 94080-4990

U.S. License No. 1048

PERJETA is a registered trademark of Genentech,

Inc.

©2012 Genentech, Inc.

433